The embodiments disclosed herein relate generally to a smart oscillating positive expiratory pressure device, and to methods for the use and assembly thereof.
Chronic obstructive pulmonary disease (COPD) and cystic fibrosis (CF) may cause an increase in the work of breathing that leads to dyspnea, respiratory muscle fatigue and general discomfort. Oscillating positive expiratory pressure (OPEP) treatments may be used as a drug-free way to clear excess mucus from the lungs of COPD and CF patients. OPEP may also be used post-operatively to reduce the risk of post-operative pulmonary complications. Typically, OPEP devices provide minimal feedback to the user or caregiver about the performance and/or effectiveness of the device during a treatment session. In addition, a large percentage (60%) of COPD patients do not adhere to prescribed therapy, with hospital systems carrying the burden of non-compliant patients that return to the hospital within 30 days. In addition, OPEP devices typically do not provide feedback regarding therapy adherence, progress tracking or proper usage technique.
Briefly stated, in one embodiment, a smart OPEP device provides feedback to the user (patient or caregiver) regarding the frequency, mean pressure and amplitude of the pressure oscillations generated during a treatment session. In addition, data and information gathered regarding the performance of the OPEP device may be archived and analyzed to provide an overview of the user's progress, which may be made available to health care providers and insurers, for example, to monitor treatment adherence. Patient specific data may be provided to monitor trends over time. Performance targets and/or limits may be set to assist the user in achieving correct techniques, and treatment effectiveness may be evaluated by surveying the patient's quality of life and linking it to performance. In addition, with performance characteristics being measured, the user may set up the device, and the user may be motivated by various feedback including counting breaths or by playing games based on the measurements.
The present embodiments, together with further objects and advantages, will be best understood by reference to the following detailed description taken in conjunction with the accompanying drawings.
It should be understood that the term “plurality,” as used herein, means two or more. The term “coupled” means connected to or engaged with, whether directly or indirectly, for example with an intervening member, and does not require the engagement to be fixed or permanent, although it may be fixed or permanent. It should be understood that the use of numerical terms “first,” “second,” “third,” etc., as used herein does not refer to any particular sequence or order of components. It should be understood that the term “user” and “patient” as used herein refers to any user, including pediatric, adolescent or adult humans, and/or animals.
The term “smart” refers to features that follow the general format of having an input, where information is entered into the system, analysis, where the system acts on or modifies the information, and an output, wherein new information leaves the system. The phrase “performance characteristics” refers to measurements, such as frequency or amplitude, which quantify how well a device is functioning. Frequency is defined as the number of oscillations in one second, however, during a typical OPEP maneuver the rate of oscillations may not be consistent. Accordingly, frequency may be defined as the inverse of the time between oscillations (1/T), measured in Hz. This second definition calculates the frequency of each oscillation and is averaged over a period of time. Max pressure is the maximum pressure for each oscillation, typically measured in cmH2O. Min pressure is the minimum pressure for each oscillation, typically measured in cmH2O. Upper pressure is the average of the max pressures for a given time period, for example one second. Lower pressure is the average of min pressures for a given time period, for example one second. Amplitude is the difference between the upper and lower pressures. Mean pressure is the average of the upper and lower pressures. True mean pressure is the average of the entire pressure waveform for a given time period. The true mean pressure is typically lower than the means pressure because the typical pressure wave generated is not uniform, i.e., is skewed towards the min pressure.
Referring to
A user, such as a patient, interacts with the OPEP device 2 via a mouthpiece 4. The OPEP device includes a housing 6 enclosing a mouthpiece chamber 48, a chamber 14, a chamber inlet 16 in communication with the mouthpiece, and one or more chamber outlets 18. Typically, OPEP devices permit the user to inhale and exhale, although some devices may permit exhalation only. The housing 6 has a front section 8, a rear section 10, and an inner casing 12, which may be separable so that the components contained therein can be periodically accessed, cleaned, or reconfigured, as required to maintain the ideal operating conditions.
The OPEP device 2 also includes an inhalation port 20, a one-way valve 22, an adjustment mechanism 24, a restrictor member 26, a vane 28, and a variable nozzle 30, or vale assembly. As seen in
The OPEP device 2 may be adapted for use with other or additional interfaces, such as an aerosol delivery device. In this regard, the OPEP device 2 is equipped with an inhalation port 20 in fluid communication with the mouthpiece 4. As noted above, the inhalation port may include a separate one-way valve 22 configured to permit a user of the OPEP device 800 both to inhale the surrounding air through the one-way valve 22 and to exhale through the chamber inlet 16, without withdrawing the mouthpiece 4 of the OPEP device 2 from the user between periods of inhalation and exhalation. In addition, the aforementioned commercially available aerosol delivery devices may be connected to the inhalation port 20 for the simultaneous administration of aerosol therapy (upon inhalation) and OPEP therapy (upon exhalation).
The exhalation flow path 40 begins at the mouthpiece 4 and is directed through the mouthpiece chamber 48 toward the chamber inlet 16, which in operation may or may not be blocked by the restrictor member 26, or valve assembly which may include a valve seat and butterfly valve. After passing through the chamber inlet 16, the exhalation flow path 40 enters the first chamber 14 and makes a 180° turn toward the variable nozzle 30. After passing through an orifice of the variable nozzle, the exhalation flow path enters the second chamber 14. In the second chamber 14, the exhalation flow path 40 may exit the second chamber 41, and ultimately the housing 6, through at least one of the chamber outlets 18. It should be understood that the exhalation flow path 40 identified by the dashed line is exemplary, and that air exhaled into the OPEP device 2 may flow in any number of directions or paths as it traverses from the mouthpiece 4 to the outlets 18.
The shaded area 50 in
Inputs
The term “input” refers to any information that enters the smart OPEP system, and may take the form of raw data from a sensor, a command to start a process or personal data entered by the user. For example, the input may be a signal from one or more input components, such as a sensor. For example, as shown in
Referring to
Referring to
At rest, the pressure in the OPEP chamber 48, 14a, 14b, is atmospheric or ambient. As pressure in the chamber increases, an upward/outward force is applied to the membrane 200, causing it to move towards the module 54. Since a measurement chamber 202, formed between the membrane 200 and the module, is sealed with the membrane, the volume of air in the measurement chamber 202 is decreased with while the pressure in the chamber 202 is increased. The control module measures the pressure change inside the sealed measurement chamber and determines the pressure inside the OPEP chamber 48 (or 14a, 14b) using a conversion algorithm. During inhalation, the pressure in the chamber 48, 14a and/or 14b, becomes negative, which imparts a downward or inward force on the membrane 202. As the flexible membrane is pulled away from the control module 54, the pressure inside the measurement chamber is decreased, or becomes negative. Again, the control module 54 measures this pressure chamber and determines the corresponding, or actual, pressure in the chamber 48. As such, the module 54 measures pressure without being in fluid communication with the chamber 48 and the user's inspiratory/expiratory flow.
Referring to
Referring to
Referring to
If the pressure inside the device is too high, the silicone bellows may not be stiff enough to resist bottoming out. As shown in
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
Referring to
Another embodiment uses a proximity sensor 136 to monitor the control nozzle 30. As the valve/vane mechanism 134 opens and closes to create the pressure oscillations, the flow within the device also oscillates. When the flow is high the control nozzle 30 is in the open state, and when the flow is low the control nozzle is in the closed state. The open/closed motion of the control nozzle may be detected and converted to frequency.
An accelerometer measures proper acceleration and can be used to calculate frequency from the vibrations as the valve/vane mechanism 26, 134 opens and closes. The accelerometer may be placed on the device in the location that provides the greatest vibration.
A microphone 140, similar to the one shown in
An LED 142 and Photo sensor 144 may be used to calculate the frequency of the oscillating mechanism. In this arrangement, the LED is located on one side of the butterfly valve 146 and the photo sensor is on the other. As the valve opens, light passes through the valve seat and is measured by the photo sensor. As the valve closes, or engages the seat 148, light is blocked from reaching the photo sensor. The timing of this data can be used to calculate the frequency.
Another LED/Photo sensor arrangement is shown in
Referring to
Input on the user's quality of life is used to calculate a QoL score which may be correlated with DFP performance. Various inputs may be used to calculate a QoL score and algorithms could be tailored or adjusted for different disease types. User input may be performed with an auxiliary input component, such as computer device, for example a smartphone app. Some examples of QoL inputs are:
Referring to
Audible and sensory/tactile (vibration) outputs and output components may also be used to provide feedback to the user. For example, sound or vibration occurs while the input is within the acceptable range, or if the input exceeds a specified limit.
A mobile device 62, or other computer interface, may function as the output component and provide an interface with a smartphone app as an output if the Smart features are not integrated into the OPEP device. The app could display real-time performance characteristics, data trends, or games that motivate the user to complete a session.
Feature: Performance Targets
This feature provides feedback to the user based on specific performance targets. For example, if the mean pressure is to be within 10 to 15 cmH2O, this feature would notify the user that their mean pressure is too high, too low, or acceptable. The performance targets can be set by the patient or health care provider, or default to limits based on generally accepted treatment protocols.
The general layout for this feature is shown below in
The performance characteristics that could be included in this feature are referred to above and herein. The following table lists exemplary performance characteristics and various suitable sensors for measuring the characteristics.
The flow chart for this feature is shown in
In operation, the user first selects the type of feedback. The “Get Type & Set Type” define the performance characteristic to be analyzed. Next, the user decides if custom targets are to be used and enters the limits. If not, default limits are set based on the performance characteristic selected. Next, the sensor 154 begins sending raw data and the selected performance characteristic is calculated. Next, a series of decisions are made based on the calculated value of the performance characteristic. If the value is greater than the upper limit, then the output is high. If the value is less than the lower limit, then the output is low. If the value is neither, than the output is OK. Next, the flow chart checks if the user has selected to end the feedback. If not, then the cycle repeats. The above logic provides 3 discreet states of feedback. If required, additional logic could be added to provide a finer resolution to the feedback.
The analysis may either be completed using a processor 158, e.g., a microcontroller, embedded in the PCB, or may be performed using an external computing device, such as mobile device, including a smartphone or tablet. As seen in Table 1, frequency may be determined from any sensor, however, pressure outputs require a pressure sensor (either direct or indirect). In order to calculate frequency from a pressure input, processing techniques such as: Peak-to-Peak time, Fourier analysis, or Auto-correlation may be used.
If the input is a sound signal it can be averaged to simplify the waveform. The simpler waveform may then be processed in the same way as a pressure signal to determine frequency. Referring to
The output for this feature can be visual 160, audible 162, or sensory 164, and can be integrated into the device. An example of an integrated solution is shown in
Referring to
The computing device, such as a mobile device including a smartphone 62, may function as the output device (and also the manual input (auxiliary input component) and analysis source). In these examples, the Smart OPEP communicates with the smartphone via a wireless protocol such as Bluetooth as shown in
Referring to
Referring to
One aspect of the embodiments disclosed herein relates to the handling of data. Data logged by the OPEP may be transferred to an external device, such as a smartphone, tablet, personal computer, etc. If such an external device is unavailable, the data may be stored internally in the OPEP in a data storage module or other memory and transferred upon the next syncing between the OPEP and external device. Software may accompany the OPEP to implement the data transfer and analysis.
In order to provide faster and more accurate processing of the data, for example from one or more various sensors, generated within the smart OPEP, data may be wirelessly communicated to a smart phone, local computing device and/or remote computing device to interpret and act on the raw sensor data.
In one implementation, the smart OPEP includes circuitry for transmitting raw sensor data in real-time to a local device, such as a smart phone. The smart phone may display graphics or instructions to the user and implement processing software to interpret and act on the raw data. The smart phone may include software that filters and processes the raw sensor data and outputs the relevant status information contained in the raw sensor data to a display on the smart phone. The smart phone or other local computing device may alternatively use its local resources to contact a remote database or server to retrieve processing instructions or to forward the raw sensor data for remote processing and interpretation, and to receive the processed and interpreted sensor data back from the remote server for display to the user or a caregiver that is with the user of the smart OPEP.
In addition to simply presenting data, statistics or instructions on a display of the smart phone or other local computer in proximity of the smart OPEP, proactive operations relating to the smart OPEP may be actively managed and controlled. For example, if the smart phone or other local computer in proximity to the smart OPEP determines that the sensor data indicates the end of treatment has been reached, or that further treatment is needed, the smart phone or other local computing device may communicate such information directly to the patient. Other variations are also contemplated, for example where a remote server in communication with the smart phone, or in direct communication with the smart OPEP via a communication network, can supply the information and instructions to the patient/user.
In yet other implementations, real-time data gathered in the smart OPEP and relayed via to the smart phone to the remote server may trigger the remote server to track down and notify a physician or supervising caregiver regarding a problem with the particular treatment session or a pattern that has developed over time based on past treatment sessions for the particular user. Based on data from the one or more sensors in the smart OPEP, the remote server may generate alerts to send via text, email or other electronic communication medium to the user, the user's physician or other caregiver.
The electronic circuitry in the smart OPEP (e.g. the controller arrangement of
Although the computer 500 is shown to contain only a single processor 502 and a single bus 508, the disclosed embodiment applies equally to computers that may have multiple processors and to computers that may have multiple busses with some or all performing different functions in different ways.
The storage device 516 represents one or more mechanisms for storing data. For example, the storage device 516 may include a computer readable medium 522 such as read-only memory (ROM), RAM, non-volatile storage media, optical storage media, flash memory devices, and/or other machine-readable media. In other embodiments, any appropriate type of storage device may be used. Although only one storage device 516 is shown, multiple storage devices and multiple types of storage devices may be present. Further, although the computer 500 is drawn to contain the storage device 516, it may be distributed across other computers, for example on a server.
The storage device 516 may include a controller (not shown) and a computer readable medium 522 having instructions 524 capable of being executed on the processor 502 to carry out the functions described above with reference to processing sensor data, displaying the sensor data or instructions based on the sensor data, controlling aspects of the smart OPEP to alter its operation, or contacting third parties or other remotely located resources to provide update information to, or retrieve data from those remotely located resources. In another embodiment, some or all of the functions are carried out via hardware in lieu of a processor-based system. In one embodiment, the controller is a web browser, but in other embodiments the controller may be a database system, a file system, an electronic mail system, a media manager, an image manager, or may include any other functions capable of accessing data items. The storage device 516 may also contain additional software and data (not shown), which is not necessary to understand the invention.
The output device 510 is that part of the computer 500 that displays output to the user. The output device 510 may be a liquid crystal display (LCD) well-known in the art of computer hardware. In other embodiments, the output device 510 may be replaced with a gas or plasma-based flat-panel display or a traditional cathode-ray tube (CRT) display. In still other embodiments, any appropriate display device may be used. Although only one output device 510 is shown, in other embodiments any number of output devices of different types, or of the same type, may be present. In one embodiment, the output device 510 displays a user interface. The input device 512 may be a keyboard, mouse or other pointing device, trackball, touchpad, touch screen, keypad, microphone, voice recognition device, or any other appropriate mechanism for the user to input data to the computer 500 and manipulate the user interface previously discussed. Although only one input device 512 is shown, in another embodiment any number and type of input devices may be present.
The network interface device 520 provides connectivity from the computer 500 to the network 526 through any suitable communications protocol. The network interface device 520 sends and receives data items from the network 526 via a wireless or wired transceiver 514. The transceiver 514 may be a cellular frequency, radio frequency (RF), infrared (IR) or any of a number of known wireless or wired transmission systems capable of communicating with a network 526 or other smart devices 102 having some or all of the features of the example computer of
The computer 500 may be implemented using any suitable hardware and/or software, such as a personal computer or other electronic computing device. The computer 500 may be a portable computer, laptop, tablet or notebook computers, smart phones, PDAs, pocket computers, appliances, telephones, and mainframe computers are examples of other possible configurations of the computer 500. The network 526 may be any suitable network and may support any appropriate protocol suitable for communication to the computer 500. In an embodiment, the network 526 may support wireless communications. In another embodiment, the network 526 may support hard-wired communications, such as a telephone line or cable. In another embodiment, the network 526 may support the Ethernet IEEE (Institute of Electrical and Electronics Engineers) 802.3x specification. In another embodiment, the network 526 may be the Internet and may support IP (Internet Protocol). In another embodiment, the network 526 may be a LAN or a WAN. In another embodiment, the network 526 may be a hotspot service provider network. In another embodiment, the network 526 may be an intranet. In another embodiment, the network 526 may be a GPRS (General Packet Radio Service) network. In another embodiment, the network 526 may be any appropriate cellular data network or cell-based radio network technology. In another embodiment, the network 526 may be an IEEE 802.11 wireless network. In still another embodiment, the network 526 may be any suitable network or combination of networks. Although one network 526 is shown, in other embodiments any number of networks (of the same or different types) may be present.
It should be understood that the various techniques described herein may be implemented in connection with hardware or software or, where appropriate, with a combination of both. Thus, the methods and apparatus of the presently disclosed subject matter, or certain aspects or portions thereof, may take the form of program code (i.e., instructions) embodied in tangible media, such as floppy diskettes, CD-ROMs, hard drives, or any other machine-readable storage medium wherein, when the program code is loaded into and executed by a machine, such as a computer, the machine becomes an apparatus for practicing the presently disclosed subject matter. In the case of program code execution on programmable computers, the computing device generally includes a processor, a storage medium readable by the processor (including volatile and non-volatile memory and/or storage elements), at least one input device, and at least one output device. One or more programs may implement or use the processes described in connection with the presently disclosed subject matter, e.g., through the use of an API, reusable controls, or the like. Such programs may be implemented in a high level procedural or object-oriented programming language to communicate with a computer system. However, the program(s) can be implemented in assembly or machine language, if desired. In any case, the language may be a compiled or interpreted language and it may be combined with hardware implementations. Although exemplary embodiments may refer to using aspects of the presently disclosed subject matter in the context of one or more stand-alone computer systems, the subject matter is not so limited, but rather may be implemented in connection with any computing environment, such as a network or distributed computing environment. Still further, aspects of the presently disclosed subject matter may be implemented in or across a plurality of processing chips or devices, and storage may similarly be spread across a plurality of devices. Such devices might include personal computers, network servers, and handheld devices, for example.
Providing feedback to users regarding their technique is one feature of the smart OPEP that will help optimize treatment. A controller, which may be located on or inside the various embodiments of the smart OPEP described herein, is in communication with one or more sensors, switches and or gauges that are tracking or controlling operation of the smart OPEP. The controller may store data gathered in a memory, integrated into the controller or implemented as a discrete non-volatile memory located in the smart OPEP, for later download to a receiving device, or may transmit data to a receiving device in real-time. Additionally, the controller may perform some processing of the gathered data from the sensors, or it may store and transmit raw data. RF transmitter and/or receiver modules may be associated with the controller on the smart OPEP to communicate with remote hand-held or fixed computing devices in real-time or at a later time when the smart OPEP is in communication range of a communication network to the remote hand-held or fixed location computing devices. The controller may include one or more of the features of the computer system 500 shown in
For clarity in displaying other features of the various Smart OPEP embodiments described, the controller circuitry is omitted from some illustrations, however a controller or other processing agent capable of at least managing the routing or storing of data from the smart OPEP is contemplated in one version of these embodiments. In other implementations, the smart OPEP may not include an onboard processor and the various sensors, gauges and switches of a particular embodiment may wirelessly communicate directly with a remotely located controller or other processing device, such as a handheld device or remote server. Data gathered by a controller or other processing device may be compared to expected or pre-programmed values in the local controller memory or other remote location to provide the basis for feedback on whether desired performance or therapy is taking place. If the controller is a more sophisticated and includes more of the computer 500 elements described in
Feature: Performance Limits
Referring to
Feature: Real-Time DFP Feedback
Previous features may only inform the user if the input is high, low, or acceptable. An additional feature provides quantitative real-time feedback of the desired performance characteristic.
All of the inputs listed in the previous features can be used for this feature:
The inputs can be analyzed to determine:
In order to display the DFP in real-time, a computer device, such as a laptop, smartphone, or tablet, or other separate device with a display is required.
Feature: DFP History
Another feature provides a way for the patient or HCP to review DFP data from previous sessions. DFP data can be displayed over time and the user can retrieve and display the data by some temporal component, including for example and without limitation day, week, month, year, or all time. This allows the user to quickly visualize trends in the performance.
Feature: Ensure Proper Setting
This feature provides feedback to the user regarding the appropriate resistance setting. In one embodiment, the OPEP device provides five (5) resistance settings which change the frequency, amplitude and mean pressure performance. For a given flow rate, increasing the resistance setting increases the frequency and pressure characteristics. In one embodiment, for example the Aerobika® OPEP device IFU, the correct resistance setting will produce an Inspiratory:Expiratory ratio (I:E ratio) of 1:3 or 1:4 for 10-20 min without excess fatigue. Therefore, the input will be used to identify the start and end of the inspiratory and expiratory cycles. Some possible inputs include a flow sensor, pressure sensor, or microphone.
A flow sensor may be placed in the mouthpiece and used to determine the I:E ratio. A single flow sensor, placed at location 1 in
A pressure sensor may be used to calculate the I:E ratio. If the pressure is negative then the flow is inspiratory, and if the pressure is positive then the flow is expiratory. The pressure sensor may be positioned as shown in
In an alternative embodiment, two (2) microphones may to be used for the calculation of the I:E ratio, similar to the dual flow sensors shown in
To analyze the I:E ratio, four (4) time points need to be determined: the start and end of inhalation (T1 and T2), and the start and end of exhalation (T3 and T4). The analysis could follow the logic shown in
The output of this feature would make recommendations to the user to either increase resistance, decrease resistance, or leave the resistance setting unchanged. An output component may be embedded in the device and be either visual, audible, or tactile as shown in
Feature: Setting Recommendation Based on Previous Data
This feature will analyze previous DFP data and make setting recommendations. This feature may calculate the I:E Ratio for each breath and then calculate the average I:E Ratio for a session. Based on the average I:E Ratio, this feature would make a setting change recommendation using the logic shown in
Feature: Proper Technique
This feature will provide the user with training and coaching on proper technique for performing an OPEP maneuver based on the IFU, and may be updated for other devices. In one embodiment, this feature may take the form of an app, and will communicate with the OPEP device via BTLE (see
A proper OPEP maneuver relies on several variables, such as I:E Ratio, frequency, pressure, and setting. These inputs have been previously discussed.
The ideal OPEP maneuver follows these steps: Inhale slowly, taking a deeper breath than normal but not filling the lungs, hold your breath and exhale actively. To analyze the first step, the app needs to learn the user's breathing pattern. This is done during the initial setup or training session and could be re-evaluated if the user's performance changes. To start, the user would inhale normally through the device in order to calculate their baseline inspiratory pressure, or IPTidal, or Tidal Volume (TV). Next, the user would inhale fully through the device to calculate their maximum inspiratory pressure, or IPmax, or Inspiratory Capacity (IC). The app would then calculate the target inspiratory pressure (IPtarget) or volume for step #1 which is more than IPtidal (or the Tidal Volume) and less than the IPmax (or Inspiratory Capacity). A starting point for the IPtarget (or target inspiratory volume) would be the average of IPtidal and IPmax (or the TV and the IC).
The next step involves holding your breath for 2-3 seconds. Breath hold=T3−T2.
Next, the user exhales actively, but not forcefully. Frequency and pressures should be within target range and exhalation should last 3-4 times longer than inhalation. Exhaling actively is a subjective description of the OPEP maneuver, therefore, the app will calculate the frequency, mean pressure and I:E ratio in real-time, and use that information and data to determine if the proper technique is being achieved.
The output of this coaching feature will guide the user toward the correct OPEP technique based on the user's breathing pattern and specific performance targets. If any of steps above are not performed correctly, the app will make suggestions to change the user's technique. For example, if the user doesn't hold their breath before exhaling, the app would offer a reminder. In another example, the app may suggest that the user increase their flow rate because the mean pressure is too low and is not within the accepted limits. To declare the user “trained”, the app may require the user to demonstrate a proper OPEP maneuver several times. The app could also play audio of a proper OPEP maneuver, which may assist the user in exhaling actively. The app may also include training videos explaining the proper technique and examples of people performing proper OPEP maneuvers. The app may also notify the user's healthcare provider (HCP) if proper technique isn't being completed.
Feature: Session Assist
In addition to the coaching feature, the Smart OPEP device can assist the user in following the correct therapy regime. Session Assist features aid the user or HCP in completing an OPEP session. For the first time user, an OPEP session can be confusing and complicated. The user needs to count the number of breaths, remember proper technique, remember when to perform ‘Huff’ coughs, and etc. For example, the Aerobika® OPEP device IFU recommends the following steps: perform 10-20 OPEP maneuvers or breaths, after at least 10 breaths, perform 2-3 ‘Huff’ coughs, repeat for 10-20 minutes twice/day on a regular base, increase to 3-4 times/day if needed.
Using the inputs defined earlier, this feature would count the number of breaths and provide feedback to the user, either with the number remaining or the number completed. The app would then remind the user to perform ‘Huff’ coughs after the appropriate number of breaths, and then repeat the breath counting/huff cough cycle for 10-20 minutes. The user may input the total number of breaths to complete or total session time as a goal and track progress. The Session Assist feature would also track the number of sessions per day, which can be used to determine the user's progress or quality of life.
Feature: Quality of Life Score
This feature transforms quantitative data into qualitative data that is easier for the user, HCP, or payer to understand. There are three (3) steps involved: determine the user's Quality of Life (QoL) score, correlate past DFP performance to QoL score, and predict QoL score based on DFP performance trends. Various inputs may be used to calculate a QoL score which will be correlated with DFP performance. Inputs may be both qualitative and quantitative. Algorithms may be tailored or adjusted for different disease types. Some examples of QoL inputs are: St. George's Respiratory questionnaire for COPD, simplified questionnaire, user's journal, steps/day, and/or number of hours the user is sedentary.
The objective is to calculate a QoL score that evolves over time as the user's condition improves or worsens. Initially, the user completes a questionnaire and a baseline QoL score is computed. The user's journal would be scanned for keywords such as: good day, bad day, cough, out of breath, etc., and the QoL score would be adjusted based on the number of times keywords appear (i.e good day=+1, out of breath=−1). The application may also calculate (or integrate with another app or device such as a FitBit) the number of steps taken per day and use this information to adjust the QoL score.
Once a QoL score has been generated, the app would determine a relationship between the QoL score and the measurements in the DFP history. This would require a period of time when the app is ‘learning’ how the two (2) variables relate. In the following example, after one week of OPEP sessions (2×/day) and daily QoL input from the user, the following linear regression equation is defined: QoL=5.6×MP−6.8 as shown in
Feature: Device Status
This feature provides feedback to the user about the device itself. Several options exist, including notifying the user, HCP or payer that the device needs to be replaced. This may take the form of a reminder in the app, or could lockout features until a new lot number or serial number is entered. The feedback may also include notifying the user when the device needs to be cleaned. Cleaning notifications could be based on the number of sessions between cleaning or changes in device performance over time.
Feature: Stakeholder Updates
A stakeholder is defined as an individual or organization, outside the patient's immediate family, that has an interest in the patient's condition, treatment, and progress. Stakeholders may be the patient's doctor, respiratory therapists, hospital, or insurance company. Some examples of stakeholder updates include: updating an insurance company with the user's usage data to monitor patient adherence and/or updating HCP with user's progress since last visit, usage data, and QoL score.
Feature: Active OPEP
Referring to
Feature: Lung Health
Referring to
Although the present invention has been described with reference to preferred embodiments, those skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention. As such, it is intended that the foregoing detailed description be regarded as illustrative rather than limiting and that it is the appended claims, including all equivalents thereof, which are intended to define the scope of the invention.
This application is a continuation of U.S. application Ser. No. 15/644,138, filed Jul. 7, 2017 and entitled “Smart Oscillating Positive Expiratory Pressure Device,” which application claims the benefit of U.S. Provisional Application No. 62/359,970, filed Jul. 8, 2016, the entire disclosure of which is hereby incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
1742740 | Watters | Jan 1930 | A |
2535844 | Emerson | Dec 1950 | A |
2882026 | Eichelman | Apr 1959 | A |
2951644 | Mahon et al. | Sep 1960 | A |
3001524 | Maison et al. | Sep 1961 | A |
3172406 | Bird et al. | Mar 1965 | A |
3269665 | Cheney | Aug 1966 | A |
3467092 | Bird et al. | Sep 1969 | A |
3490697 | Best, Jr. | Jan 1970 | A |
3580249 | Takaoka | May 1971 | A |
3584621 | Bird et al. | Jun 1971 | A |
3630196 | Bird et al. | Dec 1971 | A |
3658059 | Steil | Apr 1972 | A |
3664337 | Lindsey et al. | May 1972 | A |
3826255 | Havstad et al. | Jul 1974 | A |
3838686 | Szekely | Oct 1974 | A |
3874379 | Enfield et al. | Apr 1975 | A |
3903884 | Huston et al. | Sep 1975 | A |
3990442 | Patneau | Nov 1976 | A |
4093124 | Morane et al. | Jun 1978 | A |
4094317 | Wasnich | Jun 1978 | A |
4106503 | Rosenthal et al. | Aug 1978 | A |
4116387 | Kremer, Jr. et al. | Sep 1978 | A |
4139128 | Ewald | Feb 1979 | A |
4150071 | Pecina | Apr 1979 | A |
4183361 | Russo | Jan 1980 | A |
4198969 | Virag | Apr 1980 | A |
4206644 | Platt | Jun 1980 | A |
4210140 | James et al. | Jul 1980 | A |
4210155 | Grimes | Jul 1980 | A |
4251033 | Rich et al. | Feb 1981 | A |
4253468 | Lehmbeck | Mar 1981 | A |
4268460 | Boiarski et al. | May 1981 | A |
4291688 | Kistler | Sep 1981 | A |
4333450 | Lester | Jun 1982 | A |
4413784 | Dea | Nov 1983 | A |
4452239 | Malem | Jun 1984 | A |
4456179 | Kremer | Jun 1984 | A |
4470412 | Nowacki et al. | Sep 1984 | A |
4484577 | Sackner et al. | Nov 1984 | A |
4495944 | Brisson | Jan 1985 | A |
4508118 | Toth | Apr 1985 | A |
4509688 | Gagne et al. | Apr 1985 | A |
4588129 | Shanks | May 1986 | A |
4620670 | Hughes | Nov 1986 | A |
4622968 | Persson | Nov 1986 | A |
4627432 | Newell et al. | Dec 1986 | A |
4649911 | Knight | Mar 1987 | A |
4657007 | Carlin et al. | Apr 1987 | A |
4674491 | Brugger et al. | Jun 1987 | A |
4677975 | Edgar et al. | Jul 1987 | A |
4746067 | Svoboda | May 1988 | A |
4758224 | Siposs | Jul 1988 | A |
4792097 | Kremer, Jr. et al. | Dec 1988 | A |
4809692 | Nowacki et al. | Mar 1989 | A |
4832015 | Nowacki et al. | May 1989 | A |
4911157 | Miller | Mar 1990 | A |
4951659 | Weiler et al. | Aug 1990 | A |
4971049 | Rotariu | Nov 1990 | A |
4984158 | Hillsman | Jan 1991 | A |
5012803 | Foley et al. | May 1991 | A |
5012804 | Foley et al. | May 1991 | A |
5016627 | Dahrendorf | May 1991 | A |
5020527 | Dessertine | Jun 1991 | A |
5020530 | Miller | Jun 1991 | A |
5042467 | Foley | Aug 1991 | A |
5054477 | Terada et al. | Oct 1991 | A |
5054478 | Grychowski et al. | Oct 1991 | A |
5078131 | Foley | Jan 1992 | A |
5086765 | Levine | Feb 1992 | A |
5165392 | Small | Nov 1992 | A |
5167506 | Kilis et al. | Dec 1992 | A |
5170782 | Kocinski | Dec 1992 | A |
5209225 | Glenn | May 1993 | A |
5235969 | Bellm | Aug 1993 | A |
5241954 | Glenn | Sep 1993 | A |
5277175 | Riggs et al. | Jan 1994 | A |
5280784 | Kohler | Jan 1994 | A |
5284133 | Burns et al. | Feb 1994 | A |
5299565 | Brown | Apr 1994 | A |
5301662 | Bagwell et al. | Apr 1994 | A |
5301663 | Small, Jr. | Apr 1994 | A |
5309900 | Knoch et al. | May 1994 | A |
5312046 | Knoch et al. | May 1994 | A |
5312281 | Takahashi et al. | May 1994 | A |
5318015 | Mansson et al. | Jun 1994 | A |
5331953 | Andersson et al. | Jul 1994 | A |
5333106 | Lanpher et al. | Jul 1994 | A |
5337926 | Drobish et al. | Aug 1994 | A |
5349947 | Newhouse et al. | Sep 1994 | A |
5363842 | Mishelevich et al. | Nov 1994 | A |
5383470 | Kolbly | Jan 1995 | A |
5385140 | Smith | Jan 1995 | A |
5392648 | Robertson | Feb 1995 | A |
5398714 | Price | Mar 1995 | A |
5427089 | Kraemer | Jun 1995 | A |
5431154 | Seigel et al. | Jul 1995 | A |
5458136 | Jaser et al. | Oct 1995 | A |
5461695 | Knoch | Oct 1995 | A |
5477849 | Fry | Dec 1995 | A |
5479920 | Piper et al. | Jan 1996 | A |
5487378 | Robertson et al. | Jan 1996 | A |
5497765 | Praud et al. | Mar 1996 | A |
5503139 | McMahon et al. | Apr 1996 | A |
5505192 | Samiotes et al. | Apr 1996 | A |
5505193 | Ballini et al. | Apr 1996 | A |
5505195 | Wolf et al. | Apr 1996 | A |
5511538 | Haber et al. | Apr 1996 | A |
5511539 | Lien | Apr 1996 | A |
5515842 | Ramseyer et al. | May 1996 | A |
5520166 | Ritson et al. | May 1996 | A |
5522380 | Dwork | Jun 1996 | A |
5533497 | Ryder | Jul 1996 | A |
5533501 | Denyer | Jul 1996 | A |
5544647 | Jewett et al. | Aug 1996 | A |
5549102 | Lintl et al. | Aug 1996 | A |
5570682 | Johnson | Nov 1996 | A |
5582162 | Petersson | Dec 1996 | A |
5584285 | Salter et al. | Dec 1996 | A |
5586550 | Ivri et al. | Dec 1996 | A |
5598839 | Niles et al. | Feb 1997 | A |
5613489 | Miller et al. | Mar 1997 | A |
5617844 | King | Apr 1997 | A |
5622162 | Johansson et al. | Apr 1997 | A |
5630409 | Bono et al. | May 1997 | A |
5645049 | Foley et al. | Jul 1997 | A |
5687912 | Denyer | Nov 1997 | A |
5701886 | Ryatt | Dec 1997 | A |
5704344 | Cole | Jan 1998 | A |
5740793 | Hodson et al. | Apr 1998 | A |
5743250 | Gonda et al. | Apr 1998 | A |
5752505 | Ohki et al. | May 1998 | A |
5758638 | Kreamer | Jun 1998 | A |
5765553 | Richards et al. | Jun 1998 | A |
5792057 | Rubsamen et al. | Aug 1998 | A |
5794612 | Wachter | Aug 1998 | A |
5803078 | Brauner | Sep 1998 | A |
5809997 | Wolf | Sep 1998 | A |
5816240 | Komesaroff | Oct 1998 | A |
5819726 | Rubsamen et al. | Oct 1998 | A |
5823179 | Grychowski et al. | Oct 1998 | A |
5839429 | Marnfeldt et al. | Nov 1998 | A |
5848588 | Foley et al. | Dec 1998 | A |
5865172 | Butler et al. | Feb 1999 | A |
5875774 | Clementi et al. | Mar 1999 | A |
5881718 | Mortensen et al. | Mar 1999 | A |
5890490 | Aylsworth | Apr 1999 | A |
5899201 | Schultz et al. | May 1999 | A |
5937852 | Butler et al. | Aug 1999 | A |
5954049 | Foley et al. | Sep 1999 | A |
5988160 | Foley et al. | Nov 1999 | A |
6026807 | Puderbaugh et al. | Feb 2000 | A |
6039042 | Sladek | Mar 2000 | A |
6033841 | Verdun et al. | Apr 2000 | A |
6044841 | Verdun et al. | Apr 2000 | A |
6073628 | Butler et al. | Jun 2000 | A |
6116233 | Denyer et al. | Sep 2000 | A |
6116239 | Volgyesi | Sep 2000 | A |
6129080 | Pitcher et al. | Oct 2000 | A |
6131568 | Denyer et al. | Oct 2000 | A |
6131570 | Schuster et al. | Oct 2000 | A |
6138669 | Rocci, Jr. et al. | Oct 2000 | A |
6148815 | Wolf | Nov 2000 | A |
6176237 | Wunderlich et al. | Jan 2001 | B1 |
6179164 | Fuchs | Jan 2001 | B1 |
6192876 | Denyer et al. | Feb 2001 | B1 |
6202642 | McKinnon et al. | Mar 2001 | B1 |
6223745 | Hammarlund et al. | May 2001 | B1 |
6230704 | Durkin et al. | May 2001 | B1 |
6234167 | Cox et al. | May 2001 | B1 |
6237589 | Denyer et al. | May 2001 | B1 |
6253767 | Mantz | Jul 2001 | B1 |
6293279 | Schmidt et al. | Sep 2001 | B1 |
6338443 | Piper | Jan 2002 | B1 |
6345617 | Engelbreth et al. | Feb 2002 | B1 |
6349719 | Gonda | Feb 2002 | B2 |
6358058 | Strupat et al. | Mar 2002 | B1 |
6435177 | Schmidt et al. | Aug 2002 | B1 |
6450163 | Blacker et al. | Sep 2002 | B1 |
6470885 | Blue et al. | Oct 2002 | B1 |
6481435 | Hochrainer et al. | Nov 2002 | B2 |
6513519 | Gallem | Feb 2003 | B2 |
6543448 | Smith et al. | Apr 2003 | B1 |
6546927 | Litherland et al. | Apr 2003 | B2 |
6554201 | Klimowicz et al. | Apr 2003 | B2 |
6557549 | Schmidt et al. | May 2003 | B2 |
6578571 | Watt | Jun 2003 | B1 |
6581596 | Truitt et al. | Jun 2003 | B1 |
6584971 | Denyer et al. | Jul 2003 | B1 |
6595203 | Bird | Jul 2003 | B1 |
6606992 | Schuler et al. | Aug 2003 | B1 |
6612303 | Grychowski et al. | Sep 2003 | B1 |
6644304 | Grychowski et al. | Nov 2003 | B2 |
6651651 | Bonney et al. | Nov 2003 | B1 |
6679250 | Walker et al. | Jan 2004 | B2 |
6698421 | Attolini | Mar 2004 | B2 |
6708688 | Rubin et al. | Mar 2004 | B1 |
6748945 | Grychowski et al. | Jun 2004 | B2 |
6796513 | Fraccaroli | Sep 2004 | B2 |
6823862 | McNaughton | Nov 2004 | B2 |
6839604 | Godfrey et al. | Jan 2005 | B2 |
6848443 | Schmidt et al. | Feb 2005 | B2 |
6857427 | Ziegler et al. | Feb 2005 | B2 |
6880722 | Anderson et al. | Apr 2005 | B2 |
6883517 | Halamish | Apr 2005 | B2 |
6885684 | Ichino | Apr 2005 | B2 |
6899684 | Mault et al. | May 2005 | B2 |
6904907 | Speldrich et al. | Jun 2005 | B2 |
6904908 | Bruce et al. | Jun 2005 | B2 |
6929003 | Blacker et al. | Aug 2005 | B2 |
6932083 | Jones et al. | Aug 2005 | B2 |
6934220 | Cruitt et al. | Aug 2005 | B1 |
6958691 | Anderson et al. | Oct 2005 | B1 |
6983652 | Blakley et al. | Jan 2006 | B2 |
6990975 | Jones et al. | Jan 2006 | B1 |
6994083 | Foley et al. | Feb 2006 | B2 |
7009517 | Wood | Mar 2006 | B2 |
7013896 | Schmidt | Mar 2006 | B2 |
7036505 | Bacon et al. | May 2006 | B2 |
7051731 | Rogerson | May 2006 | B1 |
7072738 | Bonney et al. | Jul 2006 | B2 |
7080643 | Grychowski et al. | Jul 2006 | B2 |
7089786 | Walker | Aug 2006 | B2 |
7091864 | Veitch et al. | Aug 2006 | B2 |
7131439 | Blacker et al. | Nov 2006 | B2 |
7131440 | Sonntag | Nov 2006 | B2 |
7151456 | Godfrey | Dec 2006 | B2 |
7159533 | Redd et al. | Jan 2007 | B1 |
7191777 | Brand et al. | Mar 2007 | B2 |
7198172 | Harvey et al. | Apr 2007 | B2 |
7201164 | Grychowski et al. | Apr 2007 | B2 |
7201165 | Bruce et al. | Apr 2007 | B2 |
7201167 | Fink et al. | Apr 2007 | B2 |
7233228 | Lintell | Jun 2007 | B2 |
7252085 | Kunschir | Aug 2007 | B2 |
7255106 | Gallem et al. | Aug 2007 | B2 |
7261102 | Barney et al. | Aug 2007 | B2 |
7267120 | Rustad et al. | Sep 2007 | B2 |
7270123 | Grychowski et al. | Sep 2007 | B2 |
7290541 | Ivri et al. | Nov 2007 | B2 |
7331340 | Barney | Feb 2008 | B2 |
7331343 | Schmidt | Feb 2008 | B2 |
7337776 | Fishman et al. | Mar 2008 | B2 |
7383837 | Robertson et al. | Jun 2008 | B2 |
7424888 | Harvey et al. | Jun 2008 | B2 |
7404400 | Lulla et al. | Jul 2008 | B2 |
RE40591 | Denyer | Dec 2008 | E |
7458372 | Feiner et al. | Dec 2008 | B2 |
7481213 | Childers | Jan 2009 | B2 |
7495546 | Lintell | Feb 2009 | B2 |
7559322 | Foley et al. | Jul 2009 | B2 |
7568480 | Foley et al. | Aug 2009 | B2 |
7581718 | Chang | Sep 2009 | B1 |
7597099 | Jones et al. | Oct 2009 | B2 |
7600511 | Power et al. | Oct 2009 | B2 |
7621270 | Morris et al. | Nov 2009 | B2 |
7634995 | Grychowski et al. | Dec 2009 | B2 |
7661423 | Brand et al. | Feb 2010 | B2 |
7730847 | Redd et al. | Jun 2010 | B1 |
7748382 | Denyer et al. | Jul 2010 | B2 |
7748385 | Lieberman et al. | Jul 2010 | B2 |
7758886 | Jauernig et al. | Jul 2010 | B2 |
7779841 | Dunsmore et al. | Aug 2010 | B2 |
7819116 | Brand et al. | Oct 2010 | B2 |
7837648 | Blair et al. | Nov 2010 | B2 |
7841335 | Harrington et al. | Nov 2010 | B2 |
7946291 | Fink et al. | May 2011 | B2 |
7954487 | Grychowski et al. | Jun 2011 | B2 |
7971588 | Fink et al. | Jul 2011 | B2 |
7984712 | Soliman et al. | Jul 2011 | B2 |
8113194 | Boehm et al. | Feb 2012 | B2 |
8165892 | Carter et al. | Apr 2012 | B2 |
8261738 | Denyer et al. | Sep 2012 | B2 |
8333190 | Addington et al. | Dec 2012 | B2 |
8335567 | Tehrani et al. | Dec 2012 | B2 |
8336545 | Fink et al. | Dec 2012 | B2 |
8342171 | Boehm et al. | Jan 2013 | B2 |
8347878 | Schuschnig et al. | Jan 2013 | B2 |
8397712 | Foley et al. | Mar 2013 | B2 |
8403861 | Williams et al. | Mar 2013 | B2 |
D680214 | Eckstein et al. | Apr 2013 | S |
8424517 | Sutherland et al. | Apr 2013 | B2 |
8464707 | Jongejan et al. | Jun 2013 | B2 |
8474448 | Oi et al. | Jul 2013 | B2 |
8534277 | Stenzler et al. | Sep 2013 | B2 |
8550067 | Bruce et al. | Oct 2013 | B2 |
8550069 | Alelov | Oct 2013 | B2 |
8596264 | Sommer | Dec 2013 | B2 |
8607783 | Takei et al. | Dec 2013 | B2 |
8616195 | Power et al. | Dec 2013 | B2 |
8668901 | Muellinger et al. | Mar 2014 | B2 |
8671943 | Shigematsu et al. | Mar 2014 | B2 |
8707950 | Rubin | Apr 2014 | B1 |
8738395 | Hyde et al. | May 2014 | B2 |
8740808 | Curti et al. | Jun 2014 | B2 |
8807131 | Tunnell et al. | Aug 2014 | B1 |
8844520 | Foley et al. | Sep 2014 | B2 |
9022023 | Korneff | May 2015 | B2 |
9035765 | Engelhard et al. | May 2015 | B2 |
9072321 | Liu | Jul 2015 | B2 |
9072846 | Helmlinger | Jul 2015 | B2 |
9108211 | Ivri et al. | Aug 2015 | B2 |
9155846 | Kern | Oct 2015 | B2 |
9242056 | Andersen et al. | Jan 2016 | B2 |
D757926 | Van Sickle et al. | May 2016 | S |
9352107 | Von Hollen et al. | May 2016 | B2 |
9427534 | Bruin et al. | Aug 2016 | B2 |
9452317 | Arkush | Sep 2016 | B2 |
9468729 | Sutherland et al. | Oct 2016 | B2 |
D771800 | Engelhard et al. | Nov 2016 | S |
9764104 | Gumaste et al. | Sep 2017 | B2 |
9782550 | Morrison et al. | Oct 2017 | B2 |
9782551 | Morrison et al. | Oct 2017 | B2 |
9956359 | Nikander et al. | May 2018 | B2 |
9993602 | Davidson et al. | Jun 2018 | B2 |
10016567 | Denyer et al. | Jul 2018 | B2 |
10019555 | Manice et al. | Jul 2018 | B2 |
10092712 | Power et al. | Oct 2018 | B2 |
10130779 | Denyer et al. | Nov 2018 | B2 |
10220166 | Van Sickle et al. | Mar 2019 | B2 |
10258754 | Nightingale et al. | Apr 2019 | B2 |
10300239 | Brand et al. | May 2019 | B2 |
10363384 | Dyche et al. | Jul 2019 | B2 |
10406302 | Andrade et al. | Sep 2019 | B2 |
10406303 | Anandhakrishnan | Sep 2019 | B2 |
10463813 | Vasandani et al. | Nov 2019 | B2 |
10603450 | Sutherland | Mar 2020 | B2 |
10674960 | Fridman | Jun 2020 | B2 |
10751500 | Lee et al. | Aug 2020 | B2 |
10786638 | Alizoti et al. | Sep 2020 | B2 |
10894142 | Costella et al. | Jan 2021 | B2 |
D912072 | Liu et al. | Mar 2021 | S |
10953168 | Biswas et al. | Mar 2021 | B2 |
20020020762 | Selzer et al. | Feb 2002 | A1 |
20020036776 | Shimaoka | Mar 2002 | A1 |
20020073991 | Conda | Jun 2002 | A1 |
20020090601 | Strupat | Jul 2002 | A1 |
20020104531 | Malone | Aug 2002 | A1 |
20020157663 | Blacker et al. | Oct 2002 | A1 |
20020162399 | Esashi | Nov 2002 | A1 |
20030075171 | Jones et al. | Apr 2003 | A1 |
20030089366 | Sommer | May 2003 | A1 |
20030136399 | Foley et al. | Jul 2003 | A1 |
20030159694 | McNaughton | Aug 2003 | A1 |
20030189492 | Harvie | Oct 2003 | A1 |
20030197068 | Abate | Oct 2003 | A1 |
20030209238 | Peters | Nov 2003 | A1 |
20030234017 | Pelerossi et al. | Dec 2003 | A1 |
20040007231 | Zhou | Jan 2004 | A1 |
20040012556 | Yong | Jan 2004 | A1 |
20040055595 | Noymer et al. | Mar 2004 | A1 |
20040244797 | Jackson | Dec 2004 | A1 |
20050039741 | Gallem et al. | Feb 2005 | A1 |
20050087178 | Milton | Apr 2005 | A1 |
20050145243 | Trombi | Jul 2005 | A1 |
20050183718 | Wuttke et al. | Aug 2005 | A1 |
20060005834 | Aylsworth et al. | Jan 2006 | A1 |
20060011196 | Gallem et al. | Jan 2006 | A2 |
20060089545 | Ratjen et al. | Apr 2006 | A1 |
20060157052 | Foley et al. | Jul 2006 | A1 |
20060178394 | Staniforth et al. | Aug 2006 | A1 |
20070017506 | Bell et al. | Jan 2007 | A1 |
20070023036 | Grychowski et al. | Feb 2007 | A1 |
20070068513 | Kreutzmann et al. | Mar 2007 | A1 |
20070125372 | Chen | Jun 2007 | A1 |
20070204864 | Grychowski et al. | Sep 2007 | A1 |
20070235028 | Bruce et al. | Oct 2007 | A1 |
20070289590 | Kreutzmann et al. | Dec 2007 | A1 |
20080083407 | Grychowski et al. | Apr 2008 | A1 |
20080178880 | Christopher et al. | Jul 2008 | A1 |
20080230053 | Kraft | Sep 2008 | A1 |
20080257345 | Snyder et al. | Oct 2008 | A1 |
20090025718 | Denyer | Jan 2009 | A1 |
20090178672 | Mullinger et al. | Jul 2009 | A1 |
20090194104 | Van Sickle | Aug 2009 | A1 |
20090272820 | Foley et al. | Nov 2009 | A1 |
20090314292 | Overfield et al. | Dec 2009 | A1 |
20100036272 | Mace et al. | Feb 2010 | A1 |
20100191192 | Prasad et al. | Jul 2010 | A1 |
20100192948 | Sutherland et al. | Aug 2010 | A1 |
20100196483 | Muellinger et al. | Aug 2010 | A1 |
20100250280 | Sutherland | Sep 2010 | A1 |
20100252036 | Sutherland et al. | Oct 2010 | A1 |
20100324439 | Davenport | Dec 2010 | A1 |
20110137290 | Flickinger | Jun 2011 | A1 |
20110180563 | Fitchett et al. | Jul 2011 | A1 |
20110209700 | Kreutzmann et al. | Sep 2011 | A1 |
20110226237 | Morrison | Sep 2011 | A1 |
20110226242 | Von Hollen et al. | Sep 2011 | A1 |
20120012106 | Bari | Jan 2012 | A1 |
20120165693 | Williams et al. | Jun 2012 | A1 |
20120240923 | Denyer et al. | Sep 2012 | A1 |
20120266872 | Tanaka et al. | Oct 2012 | A1 |
20120285236 | Haartsen et al. | Nov 2012 | A1 |
20120285447 | Schipper et al. | Nov 2012 | A1 |
20120291779 | Haartsen et al. | Nov 2012 | A1 |
20120312302 | Cardelius et al. | Dec 2012 | A1 |
20130008436 | Von Hollen et al. | Jan 2013 | A1 |
20130034534 | Kroneberg et al. | Feb 2013 | A1 |
20130037020 | Tanaka et al. | Feb 2013 | A1 |
20130053719 | Wekell | Feb 2013 | A1 |
20130092158 | Levy et al. | Apr 2013 | A1 |
20130151162 | Harris et al. | Jun 2013 | A1 |
20130186392 | Haartsen et al. | Jul 2013 | A1 |
20130213115 | Chu | Aug 2013 | A1 |
20140000598 | Sutherland et al. | Jan 2014 | A1 |
20140000599 | Dyche et al. | Jan 2014 | A1 |
20140106324 | Adams et al. | Apr 2014 | A1 |
20140182584 | Sutherland et al. | Jul 2014 | A1 |
20140247155 | Proud | Sep 2014 | A1 |
20140257126 | Vink et al. | Sep 2014 | A1 |
20140261474 | Gonda | Sep 2014 | A1 |
20140318534 | Engelbreth | Oct 2014 | A1 |
20140352690 | Kolb et al. | Dec 2014 | A1 |
20150011906 | Wallach | Jan 2015 | A1 |
20150020804 | Van Der Mark | Jan 2015 | A1 |
20150059739 | Aslam | Mar 2015 | A1 |
20150061867 | Engelhard et al. | Mar 2015 | A1 |
20150099994 | Spencer et al. | Apr 2015 | A1 |
20150100276 | Huang et al. | Apr 2015 | A1 |
20150100335 | Engelhard et al. | Apr 2015 | A1 |
20150112707 | Manice et al. | Apr 2015 | A1 |
20150122248 | Power et al. | May 2015 | A1 |
20150122261 | Pettit | May 2015 | A1 |
20150164373 | Davis et al. | Jun 2015 | A1 |
20150174348 | Tunnell et al. | Jun 2015 | A1 |
20150174349 | Tunnell et al. | Jun 2015 | A1 |
20150224269 | Alizoti | Aug 2015 | A1 |
20150231341 | Korneff | Aug 2015 | A1 |
20150235548 | Engelhard et al. | Aug 2015 | A1 |
20150283337 | Adams et al. | Oct 2015 | A1 |
20150352281 | Pfrang | Oct 2015 | A1 |
20160045681 | Cheatham, III et al. | Feb 2016 | A1 |
20160045682 | Boyden et al. | Feb 2016 | A1 |
20160045683 | Cheatham, III et al. | Feb 2016 | A1 |
20160045685 | Hyde et al. | Feb 2016 | A1 |
20160051776 | Von Hollen | Feb 2016 | A1 |
20160058960 | Papania et al. | Mar 2016 | A1 |
20160082208 | Ballam et al. | Mar 2016 | A1 |
20160106375 | Leydon | Apr 2016 | A1 |
20160106935 | Sezan et al. | Apr 2016 | A1 |
20160129182 | Schuster et al. | May 2016 | A1 |
20160129206 | Engelbreth | May 2016 | A1 |
20160136366 | Bennett | May 2016 | A1 |
20160136367 | Varney | May 2016 | A1 |
20160144141 | Biwas et al. | May 2016 | A1 |
20160144142 | Baker et al. | May 2016 | A1 |
20160158467 | Porteous | Jun 2016 | A1 |
20160166766 | Schuster et al. | Jun 2016 | A1 |
20160184535 | Edwards et al. | Jun 2016 | A1 |
20160193436 | Khasawneh | Jul 2016 | A1 |
20160213868 | Khasawneh et al. | Jul 2016 | A1 |
20160228656 | Vasandani et al. | Aug 2016 | A1 |
20160250426 | Morrison | Sep 2016 | A1 |
20160256639 | Van Sickle et al. | Sep 2016 | A1 |
20160287139 | Luttrell | Oct 2016 | A1 |
20160314256 | Su et al. | Oct 2016 | A1 |
20160325058 | Samson et al. | Nov 2016 | A1 |
20160331917 | Bennett | Nov 2016 | A1 |
20160339187 | Smaldone | Nov 2016 | A1 |
20160339190 | Morrison et al. | Nov 2016 | A1 |
20160346489 | Finke et al. | Dec 2016 | A1 |
20160354562 | Morrison | Dec 2016 | A1 |
20170020776 | Khasawneh et al. | Jan 2017 | A1 |
20170127945 | Reed | May 2017 | A1 |
20170173282 | O'Sullivan et al. | Jun 2017 | A1 |
20170296772 | Costella et al. | Oct 2017 | A1 |
20170333645 | Alizoti et al. | Nov 2017 | A1 |
20170333661 | Bennett et al. | Nov 2017 | A1 |
20180008789 | Alizoti et al. | Jan 2018 | A1 |
20180036199 | Bougatef | Feb 2018 | A1 |
20180140252 | Luxon et al. | May 2018 | A1 |
20180161531 | Costella et al. | Jun 2018 | A1 |
20180177959 | McLoughlin et al. | Jun 2018 | A1 |
20180214649 | Peller | Aug 2018 | A1 |
20180245999 | Erdler | Aug 2018 | A1 |
20180264207 | Von Hollen et al. | Sep 2018 | A1 |
20180272080 | Porter et al. | Sep 2018 | A1 |
20180272081 | Porter et al. | Sep 2018 | A1 |
20180296124 | Karakaya et al. | Oct 2018 | A1 |
20180369509 | Power et al. | Dec 2018 | A1 |
20190038854 | Fuchs et al. | Feb 2019 | A1 |
20190160237 | O'Callaghan et al. | May 2019 | A1 |
20190298941 | Collins | Oct 2019 | A1 |
20200038611 | Isaza | Feb 2020 | A1 |
20200069893 | Vasandani et al. | Mar 2020 | A1 |
20200086069 | Riebe et al. | Mar 2020 | A1 |
20200147327 | Krasnow | May 2020 | A1 |
20200187556 | Raichman | Jun 2020 | A1 |
20200188613 | Van Sickle et al. | Jun 2020 | A1 |
20200315260 | Hubbard | Oct 2020 | A1 |
20200345588 | Merrell et al. | Nov 2020 | A1 |
20210008304 | Marcoz et al. | Jan 2021 | A1 |
20210046259 | Hasegawa et al. | Feb 2021 | A1 |
20210052225 | Shetty et al. | Feb 2021 | A1 |
20210069433 | Wang et al. | Mar 2021 | A1 |
20210077056 | Matsumoto et al. | Mar 2021 | A1 |
Number | Date | Country |
---|---|---|
2996989 | Aug 1990 | AU |
2004202959 | Jul 2004 | AU |
2020103517 | Jan 2021 | AU |
2 607 458 | Nov 2006 | CA |
2804852 | Aug 1978 | DE |
8703534 | Aug 1987 | DE |
199 02 847 | May 2000 | DE |
199 53 317 | Feb 2001 | DE |
102010024912 | Feb 2013 | DE |
0 261 649 | Sep 1987 | EP |
0 281 650 | Sep 1988 | EP |
0 414 536 | Feb 1991 | EP |
0 281 650 | Mar 1992 | EP |
0 514 085 | Nov 1992 | EP |
0 587 380 | Mar 1993 | EP |
0387222 | Jul 1993 | EP |
0 601 708 | Jun 1994 | EP |
0 641 570 | Mar 1995 | EP |
0 711 609 | Jul 1995 | EP |
0 786 263 | Jan 1997 | EP |
0824023 | Feb 1998 | EP |
0617628 | May 1998 | EP |
0 855 224 | Jul 1998 | EP |
0 938 906 | Mar 1999 | EP |
0 855 224 | Jul 1999 | EP |
0 601 708 | Mar 2000 | EP |
1 439 875 | Oct 2002 | EP |
1338296 | Aug 2003 | EP |
1 673 124 | Sep 2004 | EP |
1330283 | Sep 2006 | EP |
2 548 599 | Feb 2011 | EP |
1993642 | Jan 2012 | EP |
1670533 | Jul 2012 | EP |
2300083 | May 2013 | EP |
2609954 | Jul 2013 | EP |
2376156 | Jan 2014 | EP |
2859906 | Apr 2015 | EP |
2868339 | May 2015 | EP |
2563436 | Oct 2015 | EP |
2512566 | May 2016 | EP |
1613214 | Oct 2016 | EP |
3053620 | Oct 2016 | EP |
3097937 | Nov 2016 | EP |
2638925 | Apr 2017 | EP |
2 758111 | Sep 2017 | EP |
3219089 | Mar 2019 | EP |
3569276 | Nov 2019 | EP |
3 782 682 | Feb 2021 | EP |
3 368 114 | Mar 2021 | EP |
3 583 899 | Mar 2021 | EP |
3 653 247 | Mar 2021 | EP |
1 070 292 | Jul 1954 | FR |
93306974.2 | Mar 1993 | FR |
2 763 507 | Nov 1998 | FR |
497 530 | Dec 1939 | GB |
675524 | Jul 1952 | GB |
2 253 200 | Sep 1992 | GB |
2 299 512 | Oct 1996 | GB |
2 310 607 | Sep 1997 | GB |
2406283 | Mar 2005 | GB |
2479953 | Feb 2011 | GB |
2490770 | Nov 2012 | GB |
2512047 | Sep 2014 | GB |
2479953 | Apr 2015 | GB |
8803419 | May 1988 | WO |
9009203 | Aug 1990 | WO |
WO9010470 | Sep 1990 | WO |
WO 9215354 | Feb 1992 | WO |
WO9207599 | May 1992 | WO |
WO9312823 | Jul 1993 | WO |
9417753 | Aug 1994 | WO |
WO9507723 | Feb 1995 | WO |
WO9522365 | Aug 1995 | WO |
WO 1996037249 | Nov 1996 | WO |
WO9729799 | Aug 1997 | WO |
9826828 | Jun 1998 | WO |
WO 1998033433 | Aug 1998 | WO |
9841265 | Sep 1998 | WO |
9844974 | Oct 1998 | WO |
WO 1999008737 | Feb 1999 | WO |
WO9911310 | Mar 1999 | WO |
9940959 | Aug 1999 | WO |
9953982 | Oct 1999 | WO |
WO 2000035524 | Jun 2000 | WO |
0059565 | Oct 2000 | WO |
WO0205879 | Jan 2002 | WO |
WO0209574 | Feb 2002 | WO |
WO02058771 | Aug 2002 | WO |
WO03020349 | Mar 2003 | WO |
WO03063937 | Aug 2003 | WO |
WO03092576 | Nov 2003 | WO |
WO03107523 | Dec 2003 | WO |
WO2005042076 | May 2005 | WO |
WO2005074455 | Aug 2005 | WO |
WO2006123956 | Nov 2006 | WO |
WO2007101438 | Sep 2007 | WO |
WO2008112353 | Sep 2008 | WO |
WO 2008130658 | Oct 2008 | WO |
WO2009022139 | Feb 2009 | WO |
WO2010023591 | Mar 2010 | WO |
WO2010023591 | Mar 2010 | WO |
WO2010110682 | Sep 2010 | WO |
WO2010114392 | Oct 2010 | WO |
WO2011003017 | Jan 2011 | WO |
WO2011073806 | Jun 2011 | WO |
WO2011083377 | Jul 2011 | WO |
WO2011089486 | Jul 2011 | WO |
WO2011089489 | Jul 2011 | WO |
WO2011089490 | Jul 2011 | WO |
WO2011130183 | Oct 2011 | WO |
WO2011130583 | Oct 2011 | WO |
WO 2011135915 | Nov 2011 | WO |
WO2011135353 | Nov 2011 | WO |
WO 2011158715 | Dec 2011 | WO |
WO 2011158716 | Dec 2011 | WO |
WO2012038861 | Mar 2012 | WO |
WO2012064540 | May 2012 | WO |
WO2012173992 | Dec 2012 | WO |
WO 2013013852 | Jan 2013 | WO |
WO2013028705 | Feb 2013 | WO |
WO2013042002 | Mar 2013 | WO |
WO2013043063 | Mar 2013 | WO |
WO2013061240 | May 2013 | WO |
WO2013061248 | May 2013 | WO |
WO 2013099397 | Jul 2013 | WO |
WO 2013099398 | Jul 2013 | WO |
WO 2013099399 | Jul 2013 | WO |
WO2013098334 | Jul 2013 | WO |
WO2013124624 | Aug 2013 | WO |
WO2014004437 | Jan 2014 | WO |
WO2014033229 | Mar 2014 | WO |
WO 2014068387 | May 2014 | WO |
WO2014147550 | Sep 2014 | WO |
WO2014202923 | Dec 2014 | WO |
WO2014204511 | Dec 2014 | WO |
WO2015002652 | Jan 2015 | WO |
WO2015004554 | Jan 2015 | WO |
WO2015004559 | Jan 2015 | WO |
WO2015006701 | Jan 2015 | WO |
WO2015008013 | Jan 2015 | WO |
WO2015022595 | Feb 2015 | WO |
WO 2015042343 | Mar 2015 | WO |
WO2015030610 | Mar 2015 | WO |
WO2015031472 | Mar 2015 | WO |
WO2015036010 | Mar 2015 | WO |
WO2015036723 | Mar 2015 | WO |
WO2015052519 | Apr 2015 | WO |
WO 2015071404 | May 2015 | WO |
WO2015104522 | Jul 2015 | WO |
WO2015109259 | Jul 2015 | WO |
WO2015114285 | Aug 2015 | WO |
WO2015128173 | Sep 2015 | WO |
WO2015133909 | Sep 2015 | WO |
WO2015138454 | Sep 2015 | WO |
WO2015144442 | Oct 2015 | WO |
WO2015150029 | Oct 2015 | WO |
WO2015154864 | Oct 2015 | WO |
WO2015154865 | Oct 2015 | WO |
WO2015174856 | Nov 2015 | WO |
WO2015178907 | Nov 2015 | WO |
WO2016025553 | Feb 2016 | WO |
WO2016030521 | Mar 2016 | WO |
WO2016033419 | Mar 2016 | WO |
WO2016033421 | Mar 2016 | WO |
WO2016043601 | Mar 2016 | WO |
WO2016048435 | Mar 2016 | WO |
WO2016049066 | Mar 2016 | WO |
WO2016060863 | Apr 2016 | WO |
WO 2016079461 | May 2016 | WO |
WO2016075525 | May 2016 | WO |
WO-2016079461 | May 2016 | WO |
WO2016081294 | May 2016 | WO |
WO2016085988 | Jun 2016 | WO |
WO2016090260 | Jun 2016 | WO |
WO 2016110804 | Jul 2016 | WO |
WO2016111633 | Jul 2016 | WO |
WO2016116591 | Jul 2016 | WO |
WO2016162699 | Oct 2016 | WO |
WO2016165029 | Oct 2016 | WO |
WO2016181048 | Nov 2016 | WO |
WO 2017071879 | May 2017 | WO |
WO 2017178776 | Oct 2017 | WO |
WO 2017187116 | Nov 2017 | WO |
WO 2017194906 | Nov 2017 | WO |
WO 2018083711 | May 2018 | WO |
WO 2018172562 | Sep 2018 | WO |
WO 2018172563 | Sep 2018 | WO |
WO 2019007950 | Jan 2019 | WO |
WO 2019236896 | Dec 2019 | WO |
WO 2019236899 | Dec 2019 | WO |
Entry |
---|
PCT Notification of the International Search Report and Written Opinion of the International Search Authority dated Jan. 5, 2018, 10 pgs. |
Product information excerpt, Boehringer Ingelheim, from web address: http://www.torpex.com/product_information/, Aug. 11, 2003 (4 pages). |
Product Information, Boerhinger Ingelheim, “Introducing TORPEX™ (aerosol albuteral sulfate): The Ultimate Tool for Equine Inhalation Treatment”, from website http://www.torpex.com/product_information/, Mar. 21, 2002, pp. 1-3. |
PARI LC PLUS Instructions for Use (GB), PARI GmbH, dated Jul. 2001. |
Photographs of nebulizer manufactured by PARI GmbH with detachable gas flow interrupter believed to have been publicly available prior to Feb. 13, 1996. |
YouTube Video of “Revolizer Inhaler for Asthma Treatment”, Cipla Company, dated Sep. 14, 2010: http://www.youtube.com/watch?v=2xrl14KQITw. |
Indian Examination Report for Application No. 201917022769 dated Dec. 17, 2021 (7 pages). |
Number | Date | Country | |
---|---|---|---|
20210290870 A1 | Sep 2021 | US |
Number | Date | Country | |
---|---|---|---|
62359970 | Jul 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15644138 | Jul 2017 | US |
Child | 17138476 | US |